[1] [1] BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.

[3] [3] ZHANG Y, ZHOU Y, MAO F, et al. Ki-67 index, progesterone receptor expression, histologic grade and tumor size in predicting breast cancer recurrence risk: a consecutive cohort study[J]. Cancer Commun (Lond), 2020, 40(4): 181-193.

[5] [5] REISWICH V, SCHMIDT C E, LENNARTZ M, et al. GATA3 expression in human tumors: a tissue microarray study on 16, 557 tumors[J]. Pathobiology, 2023, 90(4): 219-232.

[6] [6] TAKAKU M, GRIMM S A, DE KUMAR B, et al. Cancer-specific mutation of GATA3 disrupts the transcriptional regulatory network governed by Estrogen Receptor alpha, FOXA1 and GATA3[J]. Nucleic Acids Res, 2020, 48(9): 4756-4768.

[8] [8] OKCU O, SEN B, OZTURK C, et al. GLUT-1 expression in breast cancer[J]. Turk Patoloji Derg, 2022, 38(2): 114-121.

[9] [9] LIN J, DING Q, ZHANG G, et al. Study on PI3k gene expression in breast cancer samples and its association with clinical factors and patient survival[J]. Cell Mol Biol, 2022, 67(4): 321-327.

[10] [10] KATSURA C, OGUNMWONYI I, KANKAM H K, et al. Breast cancer: presentation, investigation and management[J]. Br J Hosp Med (Lond), 2022, 83(2): 1-7.

[11] [11] JOKAR N, VELIKYAN I, AHMADZADEHFAR H, et al. Theranostic approach in breast cancer: a treasured tailor for future oncology[J]. Clin Nucl Med, 2021, 46(8): e410-e420.

[14] [14] QUERZOLI P, PEDRIALI M, RINALDI R, et al.GATA3 as an adjunct prognostic factor in breast cancer patients with less aggressive disease: a study with a review of the literature[J]. Diagnostics (Basel), 2021, 11(4): 604.

[15] [15] YOON E C, WANG G, PARKINSON B, et al. TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma[J]. Hum Pathol, 2022, 125: 97-107.

[16] [16] DIDONNA S C, NAGORNYUK A, ADHIKARI N, et al. P4HTM: a novel downstream target of GATA3 in breast cancer[J]. Res Sq, 2023: rs. 3. rs-2622989.